|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
3/2025
vol. 100 Case report
Different clinical manifestations of Mycoplasma pneumoniae infection in children: a case series
Nina Urantówka
1
,
Wiktoria Tomaszewska
2
,
Agata Chobot
3, 4
,
Marta Bokszczanin
3, 4
Pediatr Pol 2025; 100 (3): 281-285
Online publish date: 2025/09/24
Article file
- Different clinical.pdf
[0.60 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Lipińska-Opałka A, Wawrzyniak A, Milart J, et al. Variety of clinical manifestations of Mycoplasma pneumoniae infection. Case report. Pediatr Fam Med 2013; 9: 374-378. 2.
Danner MT, Binns HC, Nguyen K, et al. Resurgence of pediatric Mycoplasma pneumoniae infections in Southeast Texas, Nov 2023-June 2024. J Pediatric Infect Dis Soc 2025; 14: piae119. DOI: 10.1093/jpids/piae119. 3.
Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: a potentially severe infection. J Clin Med Res 2018; 10: 535-544. 4.
Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 2018; 72: 3158-3176. 5.
Heuer R, Paulmann M, Annecke T, et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) – Part 1: diagnosis, initial management, and immunomodulating systemic therapy. J Dtsch Dermatol Ges 2024; 22: 1448-1466. 6.
Paulmann M, Heuer R, Annecke T, et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) – Part 2: supportive therapy of EN in the acute and post-acute stages. J Dtsch Dermatol Ges 2024; 22: 1576-1593. 7.
Yang S, Lu S, Guo Y, et al. A comparative study of general and severe mycoplasma pneumoniae pneumonia in children. BMC Infect Dis 2024; 24: 449. DOI: 10.1186/s12879-024-09340-x. 8.
Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe 2024; 5: e100-e101. DOI: 10.1016/S2666-5247(23)00344-0. 9.
Meyer Sauteur PM, Beeton ML; ESGMAC the ESGMAC MAPS study group. Mycoplasma pneumoniae: gone forever? Lancet Microbe 2023; 4: e763. DOI: 10.1016/S2666-5247(23)00182-9. 10.
Rowlands RS, Meyer Sauteur PM, Beeton ML, on behalf of the Escmid Study Group For Mycoplasma And Chlamydia Infections Esgmac. Mycoplasma pneumoniae: not a typical respiratory pathogen. J Med Microbiol 2024; 73: 001910. DOI: 10.1099/jmm.0.001910. 11.
Li J, Zhang H, Guo J, et al. Clinical features of Mycoplasma pneumoniae pneumonia in children without fever. BMC Pediatr 2024; 24: 52. DOI: 10.1186/s12887-023-04512-1. 12.
Piasecka Z, Knop-Chodyła, K, Wesołek-Bielaska E, et al. Different faces of Mycoplasma pneumoniae in children – cardiological and skin complications – case reports and literature review. Quality in Sport 2024; 27: 55032. DOI: 10.12775/QS.2024.27.55032. 13.
Rueda ZV, Aguilar Y, Maya MA, et al. Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents. BMC Pediatr 2022; 22: 169. DOI: 10.1186/s12887-022-03235-z. 14.
Li F, Zhang Y, Shi P, et al. Mycoplasma pneumoniae and adenovirus coinfection cause pediatric severe community-acquired pneumonia. Microbiol Spectr 2022; 10: e0002622. DOI: 10.1128/spectrum.00026-22. 15.
Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect 2021; 54: 557-565. 16.
Gao L, Sun Y. Laboratory diagnosis and treatment of Mycoplasma pneumoniae infection in children: a review. Ann Med 2024; 56: 2386636. DOI: 10.1080/07853890.2024.2386636. 17.
Liu J, He R, Zhang X, et al. Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia. Front Cell Infect Microbiol 2023; 13: 1135228. DOI: 10.3389/fcimb.2023.1135228. 18.
Oishi T, Ouchi K. Recent trends in the epidemiology, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae. J Clin Med 2022; 11: 1782. DOI: 10.3390/jcm11071782. 19.
Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016; 7: 974. DOI: 10.3389/fmicb.2016.00974. 20.
Lipsett SC, Hall M, Ambroggio L, et al. Antibiotic choice and clinical outcomes in ambulatory children with community-acquired pneumonia. J Pediatr 2021; 229: 207-215.e1. doi: 10.1016/j.jpeds.2020.10.005. 21.
Xie P, Zhang Y, Qin Y, et al. Macrolide resistance in Mycoplasma pneumoniae in adult patients. Front Cell Infect Microbiol 2025; 15: 1496521. DOI: 10.3389/fcimb.2025.1496521. 22.
Kim K, Jung S, Kim M, et al. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e2220949. DOI: 10.1001/jamanetworkopen.2022.20949. 23.
Wang YS, Zhou YL, Bai GN, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr 2024; 20: 901-914. 24.
Jiang Z, Li S, Zhu C, et al. Mycoplasma pneumoniae Infections: Pathogenesis and Vaccine Development. Pathogens 2021; 10: 119. DOI: 10.3390/pathogens10020119.
Copyright: © 2025 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
POLSKI
